Novo Holdings Verve Therapeutics, Inc. Transaction History

Novo Holdings

$1.43 Billion
Q3 2024

A detailed history of Novo Holdings transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Novo Holdings holds 2,400,000 shares of VERV stock, worth $13 Million. This represents 0.81% of its overall portfolio holdings.

Number of Shares

2,400,000

Previous 2,400,000 -0.0%

Holding current value

$13 Million

Previous $11.7 Million 0.82%

% of portfolio

0.81%

Previous 0.84%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.76 - $12.79 $1.9 Million - $5.12 Million	400,000 Added 20.0%	2,400,000 $11.7 Million
Q4 2023 Feb 14, 2024	BUY	$8.84 - $18.7 $17.7 Million - $37.4 Million	2,000,000 New	2,000,000 $27.9 Million
Q2 2023 Aug 14, 2023	SELL	$13.34 - $19.9 $9.34 Million - $13.9 Million	-700,000 Reduced 58.33%	500,000 $9.38 Million
Q1 2023 May 15, 2023	BUY	$14.3 - $24.01 $4.13 Million - $6.94 Million	288,889 Added 31.71%	1,200,000 $17.3 Million
Q3 2022 Nov 14, 2022	SELL	$15.63 - $41.49 $249,908 - $663,383	-15,989 Reduced 1.72%	911,111 $31.3 Million
Q2 2022 Aug 15, 2022	BUY	$11.14 - $23.17 $1.97 Million - $4.1 Million	177,100 Added 23.61%	927,100 $14.2 Million
Q1 2022 May 16, 2022	BUY	$20.92 - $39.36 $1.05 Million - $1.97 Million	50,000 Added 7.14%	750,000 $17.1 Million
Q4 2021 Feb 14, 2022	BUY	$31.94 - $54.82 $3.19 Million - $5.48 Million	100,000 Added 16.67%	700,000 $25.8 Million
Q3 2021 Nov 15, 2021	SELL	$46.0 - $73.99 $8.89 Million - $14.3 Million	-193,265 Reduced 24.36%	600,000 $28.2 Million
Q2 2021 Aug 16, 2021	BUY	$31.92 - $60.25 $25.3 Million - $47.8 Million	793,265 New	793,265 $47.8 Million

Others Institutions Holding VERV

# of Institutions

186

Shares Held

73.3M

Call Options Held

85K

Put Options Held

215K

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $324M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Novo Holdings, based on Form 13F filings with the SEC.

News

Stay updated on Novo Holdings with notifications on news.

Account